LTR Pharma Secures Ethics Approval for SPONTAN® Phase II Study, Recruitment to Begins Early 2026
By API User
3 December 2025 – Melbourne, Australia | LTR Pharma Limited (ASX:LTP) has today announced it has received Human Research Ethics Committee (HREC) approval from Bellberry (NHMRC-certified) for its SPONTAN® Phase II pharmacokinetic and multiple-dose clinical study, paving the way for recruitment to commence in Q1 calendar year 2026. The Phase II study has been designed … Continued